TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A 2026 paper in The Lancet Healthy Longevity argues that sarcopenia and age-related mobility loss should be understood as problems of the wider motor system, including the brain, nerves and muscle. The authors say current evidence supports looking beyond muscle mass, but the proposed assessment approach still needs validation and has not been shown to improve outcomes or reduce costs.
A paper published in The Lancet Healthy Longevity argues that age-related weakness and mobility loss should be assessed as problems of the wider motor system, not just as loss of muscle. Its authors say the brain, spinal cord, nerves, balance and position sense can all affect movement, but the proposed approach has not yet been shown to outperform current screening or improve patient outcomes.
The authors, led by Lucas B. R. Orssatto, say sarcopenia is still commonly framed as a muscle disease even though diagnostic approaches have shifted toward measuring grip strength, walking speed and chair stands. These measures capture physical performance and, the paper says, predict outcomes such as falls, disability and death better than muscle mass alone.
The paper argues that muscle loss explains only a modest share of the decline in strength among older adults. People with similar muscle mass can have different levels of strength and mobility, the authors say, while exercise can improve function even without a measurable increase in muscle mass. They propose that aging can also weaken the signals that the nervous system sends to muscle and affect the speed and coordination needed for everyday movement.
The authors suggest clinicians continue assessing strength and walking speed while also noting how quickly a person rises from a chair, whether they become unsteady during sustained effort, changes in hand dexterity and walking difficulty while talking. They say rapid, asymmetric or disproportionate weakness warrants closer examination. The paper also calls for medication review, noting that sedatives and anticholinergic drugs can blunt motor drive. These are proposals for practice, not a validated replacement for existing screening.
Why Falls Make Muscle Health Matter
The debate has practical consequences because weakness and impaired mobility can reduce an older person’s independence and ability to manage daily tasks, and can contribute to falls. Medical Xpress reports that sarcopenia affects up to 29% of older adults living in the community, with higher rates in hospitals and residential care and among people with frailty or multiple health conditions.
The report cites Australian figures to show the scale of fall-related harm: 253,800 fall-related hospitalizations in 2024–25, and 6,722 Australians died after a fall in the preceding year. It also reports an estimated health-system cost of $5.4 billion from fall injuries. These figures describe the reported burden; they do not show that the proposed motor-system framing would prevent falls.
If future research supports the new model, it could broaden which factors clinicians assess and what treatments researchers test. The authors argue that research should look beyond strategies aimed mainly at adding muscle and evaluate interventions for their effects on strength, movement and everyday function. For now, the paper sets out a direction for investigation rather than evidence that a new care pathway works better.
Products Worth Considering
Fitbit Sense Advanced Smartwatch – Sage Grey/Silver (One Size, S & L Bands Included)
Fitbit Versa 2 Health and Fitness Smartwatch with Bonus Bands
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
As an affiliate, we earn on qualifying purchases.
How Sarcopenia Measures Have Shifted
Sarcopenia refers to substantial loss of muscle, strength and physical function associated with aging. As the paper describes it, diagnosis has moved away from relying on muscle mass alone. Grip strength, gait speed and chair-rise performance are now central because they reflect what a person can do, rather than simply how much muscle they have.
The authors say the explanation for the condition has not changed as much as its measurement: clinical and research accounts still often treat weakness as a direct consequence of muscle wasting. Their paper, titled Reframing sarcopenia as a disease of the ageing motor system, challenges that assumption. It proposes considering the full system involved in movement, from the brain and spinal cord through nerves and their connections to muscle, alongside balance and position sense.
The discussion comes as Australian primary care practices are being asked to address poor muscle health. Medical Xpress says the Australian Journal of General Practice published a proposed algorithm earlier in 2026 to guide screening, assessment and management. The Lancet Healthy Longevity paper adds a broader interpretation of what may underlie weakness; it does not replace that algorithm or establish a new standard of care.
“Reframing sarcopenia as a disease of the ageing motor system”
— Lucas B. R. Orssatto and co-authors, in The Lancet Healthy Longevity
Evidence Still Needed for New Tests
The authors acknowledge that the suggested measures have not been shown to outperform existing screens on health outcomes or cost. It is also unclear which practical tests best capture changes in the motor system, how well primary care clinicians can use them, and whether adding them would alter treatment or prevent disability and falls.
The paper argues for further research; it does not establish that every older adult with weakness has a neurological problem or that muscle-focused care should be abandoned. The source also notes that access to neuromuscular expertise is uneven in primary care. The effectiveness of interventions that target nerves as well as muscle, and the best way to combine them, remain questions for future trials.
Validation and Trials Are Next
The authors set out a five-point agenda for international working groups responsible for sarcopenia diagnostic criteria. They call for validation of practical tests, guidelines that support a staged assessment and clinical trials that measure nerve-related outcomes alongside muscle and physical function.
The next evidence needed is whether these assessments identify relevant causes of weakness more accurately and whether acting on the results helps people maintain mobility and independence. Until those findings are available, the paper’s motor-system framework is a research proposal, not proof of improved care.
Key Questions
What is sarcopenia?
Sarcopenia is a condition involving substantial loss of muscle, strength and physical function associated with aging. The paper argues that its causes and assessment should not be reduced to muscle alone.
What does the motor-system explanation include?
It includes the brain, spinal cord, nerves and their connections to muscle, as well as balance and position sense. The authors say these systems help plan, signal and coordinate movement.
Does the paper show that new tests prevent falls?
No. The authors say the proposed measures have not been shown to improve outcomes or cost-effectiveness compared with existing screens. Trials and validation studies are still needed.
What do the authors suggest clinicians assess?
Alongside strength and walking speed, they suggest observing chair-rise speed, steadiness during sustained effort, hand dexterity and walking while talking. These suggestions are not yet a validated replacement for current assessments.
Source: rss
